Overview

Bioavailability Study of Ondansetron Orally Disintegrating Tablets Under Fasting Conditions

Status:
Completed
Trial end date:
2002-09-01
Target enrollment:
Participant gender:
Summary
To compare the single-dose bioavailability of Ondansetron 8 mg oDT and Zofran 8 mg ODT
Phase:
Phase 1
Details
Lead Sponsor:
Par Pharmaceutical, Inc.
Collaborator:
Algorithme Pharma Inc
Treatments:
Ondansetron